StreetInsider.com News Articles

Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK

Wed, 10 Jun 2026 05:19:37 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).

The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful.

Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK

Wed, 10 Jun 2026 05:19:37 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).

Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK

Wed, 10 Jun 2026 05:19:37 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).

Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK

Wed, 10 Jun 2026 05:19:37 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).

Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK

Wed, 10 Jun 2026 05:19:37 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Fri, 05 Jun 2026 07:00:00 -0400

WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47^th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Goldman Sachs 47th Annual Global Healthcare Conference 2026

Fireside Chat: Tuesday, June 9, 2026, at

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Fri, 05 Jun 2026 07:00:00 -0400

Goldman Sachs 47th Annual Global Healthcare Conference 2026

Fireside Chat: Tuesday, June 9, 2026, at

Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 15 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26505503.html

Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 15 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26505503.html

Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: Flynn James E

Thu, 14 May 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260514/26497111.html

Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: Flynn James E

Thu, 14 May 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260514/26497111.html

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May